Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Sep 20;77(12):1156-64.
doi: 10.1212/WNL.0b013e31822f02e1. Epub 2011 Aug 31.

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

M Weller  1 , T Gorlia, J G Cairncross, M J van den Bent, W Mason, K Belanger, A A Brandes, U Bogdahn, D R Macdonald, P Forsyth, A O Rossetti, D Lacombe, R-O Mirimanoff, C J Vecht, R Stupp
Affiliations
Randomized Controlled Trial

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

M Weller et al. Neurology. .

Abstract

Objective: This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma.

Methods: The European Organization for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada (NCIC) CE.3 clinical trial database of radiotherapy (RT) with or without temozolomide (TMZ) for newly diagnosed glioblastoma was examined to assess the impact of the interaction between AED use and chemoradiotherapy on survival. Data were adjusted for known prognostic factors.

Results: When treatment began, 175 patients (30.5%) were AED-free, 277 (48.3%) were taking any enzyme-inducing AED (EIAED) and 135 (23.4%) were taking any non-EIAED. Patients receiving valproic acid (VPA) only had more grade 3/4 thrombopenia and leukopenia than patients without an AED or patients taking an EIAED only. The overall survival (OS) of patients who were receiving an AED at baseline vs not receiving any AED was similar. Patients receiving VPA alone (97 [16.9%]) appeared to derive more survival benefit from TMZ/RT (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.24-0.63) than patients receiving an EIAED only (252 [44%]) (HR 0.69, 95% CI 0.53-0.90) or patients not receiving any AED (HR 0.67, 95% CI 0.49-0.93).

Conclusions: VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy. Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Survival plots
(A) Overall survival: Kaplan-Meier curve per tumor treatment and antiepileptic drug (AED) status. Red curves, patients not receiving AED. Green curves, valproic acid (VPA)–treated patients. Blue curves, enzyme-inducing antiepileptic drug (EIAED)–treated patients. Solid curves (top curves), patients treated with temozolomide (TMZ)/radiotherapy (RT). Dashed curves, patients treated with RT. (B) Overall survival: Forest plot of interaction between treatment and AED. CI=confidence interval; HR=hazard ratio; E=events expected; N=number of patients treated with either RT or TMZ/RT and respective subgroups; O=events observed.
See this image and copyright information in PMC

Comment in

References

    1. Van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007;6:421–430 - PubMed
    1. Wick W, Menn O, Meisner C, et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 2005;28:391–396 - PubMed
    1. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886–1893 - PubMed
    1. Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001;12:217–219 - PubMed
    1. Ward MM, Barbaro NM, Laxer KD, Rampil IJ. Preoperative valproate administration does not increase blood loss during temporal lobectomy. Epilepsia 1996;37:98–101 - PubMed

Publication types

MeSH terms

LinkOut - more resources